Acousia Therapeutics GmbH: Acousia Therapeutics to present its first-in-class hearing loss treatment program with ACOU085 at the 2nd Inner Ear Therapeutics Summit in Boston
Acousia Therapeutics GmbH will be presenting data on the company’s clinical stage, first-in-class lead candidate ACOU085 at the Hanson Wade 2nd Inner Ear Therapeutics Summit to be held in person in Boston (MA) from June 20–23, 2022.
(Tübingen, Germany): ACOU085 is a proprietary, first-in-class, small-molecule otoprotective drug candidate, which is currently being tested in a Phase 1b clinical trial involving age-related hearing loss (ARHL) patients. Designed to modulate a biologically validated target – the KCNQ4-encoded Kv7.4 potassium channel, which is essential for maintaining auditory function – ACOU085 is being developed for the treatment and prevention of hearing loss for a number of acquired and inherited forms of sensorineural hearing loss.
ACOU085 is characterized by a unique dual mode of action, which provides acute functional enhancement and long-term protection for the terminally differentiated sensorineural outer hair cells. “Being invited to share the translational background and progress of our ACOU085 lead program with the hearing loss drug development community at the Inner Ear Therapeutics Summit is an exciting opportunity for us,” says Dr. Jonas Dyhrfjeld-Johnsen, Chief Development Officer at Acousia Therapeutics. “I look forward to stimulating discussions with our peers in Boston.”
In addition to receiving an invitation to present “Small Molecule, KCNQ4 Agonist ACOU085 for the Treatment and Prevention of Hearing Loss”, Dr. Dyhrfjeld-Johnsen will also participate as a panelist on the panel discussion “De-risking the Early Development Process: A Robust and Comprehensive Early Development Process Is Essential to Minimize Setbacks Faced in the Clinic” and in the workshop “Mind The Gap: Calling Out the Shortfalls in the Current Inner Ear Therapeutic Development Pathway and Illuminating Solutions”.
About Acousia Therapeutics
Acousia Therapeutics GmbH is a privately-held, clinical stage biotech company based in Tübingen, Germany. The company is dedicated to the identification and development of small molecules for effective prevention and treatment of different etiologies of hearing loss. Acousia Therapeutics develops drugs for local and systemic administration.
About news aktuell GmbH
As wholly owned subsidiary of dpa, news aktuell provides business and organizations with effective access to media and consumers. Via the smart tools ots and zimpel, PR content accesses all media formats, including classical print, high click-rate online portals and social networks. In addition, news aktuell publishes all its customers’ PR content on www.presseportal.de, one of the PR portals with the greatest reach in Germany. By this means, all the relevant multipliers are reached globally, from editors, via digital influencers right up to specialist bloggers and interested consumers. news aktuell has been on the market since 1989. The company, with a staff complement of more than 135, has its headquarters in Hamburg. Other offices are in Berlin, Dusseldorf, Frankfurt und Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
iMaps Capital Markets expands product portfolio with actively managed certificate for AI trading strategy19.5.2022 09:45:54 CEST | Pressemelding
With its newly launched Exchange Traded Instrument (ETI), iMaps Capital Markets is pursuing a trading strategy supported by artificial intelligence in order to benefit from developments on the international currency markets.
Erste Foundation: Notification - #TimeToDecide22: Questions on the Future of the EU, Ukraine, Russia and the Western Balkan Countries12.5.2022 11:16:28 CEST | Press release
The summit will be livestreamed from 9 a.m. to 8 p.m.
Northern European Rhetoric Championships to take place in Luebeck, Germany2.5.2022 13:59:50 CEST | Press release
Danish, German, Norwegian and Swedish speakers compete on online Contests on May 7th and 8th, 2022 / Live conference in Luebeck, Germany on May 14th and 15th
HoGA Capital AG: Thousands of visitors marveled at Castello CUBE during Biennale – European premiere for unique golden artwork in Venice22.4.2022 09:54:48 CEST | Press release
The Castello CUBE is a unique artwork. Never before in history has this much gold been worked into one artwork. Today, thousands of visitors enjoyed the rare opportunity to marvel at the CUBE during the Venice Biennale, where – under the highest security precautions – Niclas Castello’s work was exhibited for a few hours near the Ca’ di Dio.
HoGA Capital AG: The Castello CUBE celebrates European premiere during the Venice Biennale19.4.2022 08:50:32 CEST | Press release
(Venice, Italy): – The first public display of this unique artwork took place in New York City’s Central Park in early February, making headlines worldwide. Now, this April, the Castello CUBE is coming to Europe. For a few hours, it will be exhibited in a well-known, public space in Venice, accessible to everyone. For the first time, visitors will be allowed to touch this extraordinary artwork. Art historians such as Dr. Dieter Buchhart have already described “The Castello CUBE” as “unique in the history of art”. Weighing 186 kilograms, the work is made of pure, 24-carat, 999.9 fine gold. For security reasons, the location and time of the exhibition will be revealed only 24 hours beforehand. For further information, please send your request via email@example.com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom